Vimta Labs Limited — PPTs, 20-07-2026: Investor Presentation

Vimta Labs kicked off FY27 with strong Q1 results. Total Income jumped 13.7% year-over-year to Rs 112.9 Cr. Net Profit (PAT) grew 11.4% YoY to Rs 21.0 Cr, while EBITDA rose 16.0% to Rs 41.1 Cr, maintaining a solid 36.4% margin. Basic EPS was Rs 4.7. The company holds top positions in India across key segments like Pharma Analytical, Food & Environment, and Preclinical research, indicating broad-based performance.

Strategically, Vimta is pushing for growth via capacity expansions, new service innovations, and entering fresh markets. Demand for safe drugs, quality food, reliable electronics, and environmental testing are major tailwinds. In Q1 FY27, the company deployed Rs 18.0 Cr in capital expenditure, reflecting ongoing investments in its advanced lab infrastructure. Management foresees sustained momentum, propelled by supportive market trends and rising requirements for independent testing.